Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: January 9, 2020

Healthcare Administrative Costs Are Three Times The Cost of Drugs  

April 24, 2025January 9, 2020 by Prahsant Kumar

The high cost of healthcare in the US is often blamed on the high cost of prescription drugs, however, a recent study showed that the administrative costs play a much bigger role in our increased medical bills. The US healthcare costs is often compared to that in Canada, with laws being created to reimport drugs … Read more

Categories Blog

Faster Approval Rates Show Increased FDA-Industry Collaboration 

April 24, 2025January 9, 2020 by Prahsant Kumar

For the last few years FDA has been approving more than 40 new drugs each year, a trend that continued in 2019 with the approval of 48 new drugs and biologics. But it is important to look beyond the numbers to fully understand the trend behind these. First let’s look at the numbers. This year’s … Read more

Categories Blog

Recent Posts

  • From In silico to In vivo: Orchestrating AI for Breakthrough Therapeutics
  • Navigating the Hallucination Risks of Regulatory AI
  • Beyond the P-Value: Navigating the FDA’s New Bayesian Guidance for Drugs and Biologics
  • The Lean IND: Operationalizing the “Least Burdensome” Mandate
  • Beyond the LAL: Critical Updates to Bacterial Endotoxins and Pyrogen Testing

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.